Oncology has entered a fascinating era. Today, however, we understand that the immune system is not merely a bystander in this disease — it is a central player in the fight against cancer.

Immunotherapy has demonstrated that, when properly activated, the immune system can recognize and attack tumor cells with remarkable precision. But this raises a key question: what happens when we combine immunotherapy with drugs targeted against specific genetic and molecular alterations within the tumor?

The answer is promising. In many cases, these therapies can act synergistically — meaning they enhance each other’s effects. Nevertheless, risks also exist, and understanding the balance between benefit and toxicity is essential.

Below, we explore some of the most relevant targeted agents and how they may interact with immunotherapy.

 

PARP Inhibitors: Exploiting Tumor DNA Fragility

PARP (poly ADP-ribose polymerase) inhibitors are primarily used in breast and ovarian cancers with mutations in genes such as BRCA1, BRCA2, or PALB2. These genes are involved in DNA repair. When altered, tumor cells already have a reduced capacity to repair genetic damage.

PARP is another protein involved in DNA repair. By inhibiting it, DNA damage accumulates until the tumor cell can no longer survive. This phenomenon is known as synthetic lethality.

Importantly, the effect is not limited to direct tumor cytotoxicity. PARP inhibitors have been shown to increase PD-L1 expression, a molecule involved in immune evasion. This suggests that they may render tumors more susceptible to PD-1 or PD-L1 inhibitors.

Some clinical studies have shown improved response rates with the combination compared to either drug alone, even in patients without BRCA mutations. Although overall results remain moderate, the concept is solid: inducing genetic damage may make tumors more visible to the immune system.

 

CDK4/6 Inhibitors: From “Cold” to “Hot” Tumors

CDK4/6 inhibitors, such as palbociclib, block proteins that regulate the cell cycle, thereby slowing tumor proliferation. They are mainly used in hormone receptor–positive breast cancer.

However, their impact extends beyond growth control. Preclinical studies have shown that these agents can modulate the immune response. For example, they:

• Increase interferon production
• Enhance tumor antigen presentation
• Decrease regulatory T cells (Tregs), which normally suppress immune responses
• Promote cytotoxic CD8+ T-cell activity

In simple terms, they may convert a “cold” tumor — with limited immune cell infiltration — into a “hot” or inflamed tumor that is more responsive to immunotherapy.

While more clinical data in humans are needed, the biological rationale for synergy is compelling.

 

EGFR Inhibitors: Potential with Caution

Epidermal growth factor receptor (EGFR) inhibitors block signaling pathways that drive tumor growth and are used in cancers such as lung and colorectal cancer.

Theoretically, combining them with immunotherapy could be beneficial. However, clinical experience has revealed significantly increased adverse events, particularly hepatic toxicity, when combined with PD-1 or PD-L1 inhibitors.

An important observation is that treatment sequence appears to influence risk. When immunotherapy precedes EGFR inhibition, immune-related adverse events may be more frequent.

This scenario reminds us that synergy depends not only on which drugs are combined, but also on how and when they are administered.

 

Estrogen Inhibitors: Impact on the Immune System

In hormone receptor–positive breast cancer, agents such as tamoxifen, fulvestrant, and letrozole are widely used. Traditionally, they are viewed as blocking hormonal stimulation of the tumor.

However, estrogen also influences the immune system. It may increase immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs) and reduce CD8+ T-cell infiltration within the tumor microenvironment.

Therefore, estrogen inhibition may enhance antitumor immunity beyond its direct effect on cancer cells.

 

VEGF Inhibitors: Breaking Immune Barriers

VEGF is best known for promoting angiogenesis within tumors. However, it also plays a significant role in immunosuppression.

Excess VEGF:

• Impairs immune cell infiltration
• Increases regulatory populations such as MDSCs and Tregs
• Inhibits dendritic cell maturation

In other words, it creates a functional barrier against the immune system.

VEGF inhibitors, such as bevacizumab or axitinib, not only reduce angiogenesis but may also reverse aspects of immune suppression. Clinical studies have shown improvements in progression-free survival when combined with immunotherapy.

This is a clear example of how a drug initially designed to block blood vessel formation can also function as an immune modulator.

 

Maraviroc (CCR5 Inhibitor): Reprogramming the Microenvironment

Maraviroc, originally approved for HIV treatment, blocks the CCR5 receptor. In cancer, activation of the CCL5/CCR5 axis can stimulate tumor proliferation, increase glycolytic metabolism, and recruit immunosuppressive cells.

By blocking CCR5, maraviroc may:

• Reduce tumor proliferation
• Decrease immunosuppressive cytokines such as IL-10 and TGF-β
• Shift macrophages from a pro-tumoral M2 phenotype to an antitumoral M1 phenotype
• Reprogram MDSCs
• Inhibit VEGF signaling and metastasis

It is a notable example of how a drug can have applications beyond its original indication.

 

MEK Inhibitors: Protecting T Cells

MEK inhibitors have shown modest results when combined with immunotherapy in microsatellite-stable (MSS) metastatic colorectal cancer, a group that typically responds poorly to immunotherapy.

These agents are thought to reduce immunosuppressive mediators such as COX-2 and Arg1 while increasing cytotoxic T-cell infiltration. They may also decrease T-cell apoptosis during chronic stimulation, helping prevent functional exhaustion.

Although results are still preliminary, this represents an interesting strategy for enhancing immunotherapy in traditionally resistant tumors.

 

ALK Inhibitors: A Reminder About Toxicity

Not all combinations yield clinical benefit. Some studies have reported severe hepatic toxicity when ALK inhibitors are combined with immunotherapy.

This point is crucial: the pursuit of synergy must never compromise patient safety. Responsible research involves identifying both opportunities and risks.

 

CXCR4 and DDR2 Inhibitors: Emerging Targets

The CXCR4 receptor is involved in cell migration and may contribute to tumor fibrosis, creating a physical barrier to immune cell infiltration. In experimental models, CXCR4 blockade has led to increased T-cell infiltration and improved response to immunotherapy.

Similarly, DDR2 inhibitors such as dasatinib have demonstrated increased CD8+ T-cell infiltration when combined with PD-1 inhibitors in preclinical models.

Although further human studies are required, these approaches broaden the therapeutic landscape.

Figure 1. Schematic representation of selected targeted therapies and their immunomodulatory effects within the tumor microenvironment, illustrating potential synergy with immunotherapy. (1) PARP inhibitors: Induce synthetic lethality in DNA repair–deficient tumors and may enhance sensitivity to PD-1/PD-L1 blockade. (2) CDK4/6 inhibitors: Arrest the cell cycle and enhance antigen presentation, promoting a more immunogenic tumor microenvironment. (3) EGFR inhibitors: Block proliferative signaling; combination with immunotherapy requires caution due to potential toxicity. (4) Estrogen inhibitors: Reduce hormonal stimulation and may decrease immunosuppressive cell populations. (5) VEGF inhibitors: Inhibit angiogenesis and facilitate T-cell infiltration by reducing immune suppression. (6) COX-2 / MEK inhibitors: Decrease immunosuppressive signaling and enhance cytotoxic T-cell activity.

 

The central message is clear: many targeted therapies do more than act directly on tumor cells. They also reshape the immune microenvironment. Some remove physical barriers. Others reduce immunosuppressive cells. Others increase tumor antigen visibility.

When strategically combined with immunotherapy, the effect may exceed the sum of its parts.

However, personalization is essential. The tumor’s molecular profile, treatment sequencing, and the patient’s immune status all significantly influence outcomes.

Immunotherapy is not a standalone solution, but part of an evolving therapeutic ecosystem. The future of cancer treatment appears to lie in rational combinations built on solid scientific foundations.

Synergy is not merely a theoretical concept. It is a tangible opportunity to improve clinical outcomes. Harnessing it requires understanding, strategy, and a patient-centered approach.

The revolution continues — and each advance brings us closer to more effective, personalized, and balanced cancer therapies.

 

Main reference:

Williams, J. R. (2019). The immunotherapy revolution the immunotherapy revolution: The best New Hope for saving cancer patients’ lives. Independently Published.